Skip to main content
Top

Open Access 05-04-2025 | Type 2 Diabetes | Review

Clinical use of polygenic scores in type 2 diabetes: challenges and possibilities

Authors: Rashmi B. Prasad, Liisa Hakaste, Tiinamaija Tuomi

Published in: Diabetologia

Login to get access

Abstract

Resulting from a combination of genetic and environmental factors, type 2 diabetes is highly heterogeneous in manifestation and disease progression, with the only common feature being chronic hyperglycaemia. In spite of vigorous efforts to elucidate the pathogenetic origins and natural course of the disease, there is still a lack of biomarkers and tools for prevention, disease stratification and treatment. Genome-wide association studies have reported over 1200 variants associated with type 2 diabetes, and the decreased cost of generating genetic data has facilitated the development of polygenic scores for estimating an individual’s genetic disease risk based on combining effects from most—or all—genetic variants. In this review, we summarise the current knowledge on type 2 diabetes-related polygenic scores in different ancestries and outline their possible clinical role. We explore the potential applicability of type 2 diabetes polygenic scores to quantify genetic liability for prediction, screening and risk stratification. Given that most genetic risk loci are determined from populations of European origin while other ancestries are under-represented, we also discuss the challenges around their global applicability. To date, the potential for clinical utility of polygenic scores for type 2 diabetes is limited, with such scores outperformed by clinical measures. In the future, rather than predicting risk of type 2 diabetes, the value of polygenic scores may be in stratification of the severity of disease (risk for comorbidities) and treatment response, in addition to aiding in dissecting the pathophysiological mechanisms involved.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ (2017) Textbook of diabetes. Wiley-Blackwell, Chichester, UK Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ (2017) Textbook of diabetes. Wiley-Blackwell, Chichester, UK
20.
go back to reference Bjornstad P, Drews K, Zeitler PS (2021) Long-term complications in youth-onset type 2 diabetes. Reply. N Engl J Med 385:2016PubMed Bjornstad P, Drews K, Zeitler PS (2021) Long-term complications in youth-onset type 2 diabetes. Reply. N Engl J Med 385:2016PubMed
38.
go back to reference Garg D, Naugler C, Bhella V, Yeasmin F (2018) Chronic kidney disease in type 2 diabetes: does an abnormal urine albumin-to-creatinine ratio need to be retested? Can Fam Physician 64:e446–e452PubMedPubMedCentral Garg D, Naugler C, Bhella V, Yeasmin F (2018) Chronic kidney disease in type 2 diabetes: does an abnormal urine albumin-to-creatinine ratio need to be retested? Can Fam Physician 64:e446–e452PubMedPubMedCentral
43.
95.
go back to reference Yajnik CS, Kinare A, Chinchwadkar M et al (2024) Slower liver growth in-utero predicts the risk of prediabetes at 18 years of age, a DOHaD jump from birth size to organogenesis: novel human data in the Pune Maternal Nutrition Study (PMNS). Diabetologia 67(Suppl 1):1–593. https://doi.org/10.1007/s00125-024-06226-0CrossRef Yajnik CS, Kinare A, Chinchwadkar M et al (2024) Slower liver growth in-utero predicts the risk of prediabetes at 18 years of age, a DOHaD jump from birth size to organogenesis: novel human data in the Pune Maternal Nutrition Study (PMNS). Diabetologia 67(Suppl 1):1–593. https://​doi.​org/​10.​1007/​s00125-024-06226-0CrossRef
Metadata
Title
Clinical use of polygenic scores in type 2 diabetes: challenges and possibilities
Authors
Rashmi B. Prasad
Liisa Hakaste
Tiinamaija Tuomi
Publication date
05-04-2025
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-025-06419-1

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more